Aytu BioPharma, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
AYTU Nasdaq 2840 aytubio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aytu BioPharma, Inc.

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Feb 5th, 2026 3:56 am
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... - Feb 3rd, 2026 10:02 pm
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Feb 3rd, 2026 4:15 pm
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - Feb 3rd, 2026 2:05 pm
New Strong Sell Stocks for February 2nd - Feb 2nd, 2026 3:37 am
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - Jan 27th, 2026 2:05 pm
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - Jan 20th, 2026 2:05 pm
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - Jan 20th, 2026 7:00 am
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - Jan 13th, 2026 2:15 pm
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - Jan 12th, 2026 6:00 am
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - Dec 18th, 2025 7:00 am
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Dec 15th, 2025 7:00 am
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Nov 24th, 2025 2:05 pm
Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Nov 21st, 2025 5:40 am
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... - Nov 13th, 2025 10:02 pm
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - Nov 13th, 2025 3:20 pm
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results - Nov 13th, 2025 2:05 pm
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 7:10 am
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates - Nov 6th, 2025 3:35 pm
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 - Nov 5th, 2025 2:05 pm